AlphaBiomics was founded by prominent scientists and entrepreneurs from industry and academia. For the past several years, our team has been committed to investigating the role of the microbiome in health and disease. More recently, we have expanded our interest to the emerging field of pharmacomicrobiomics. Given the highly variable clinical response to drugs, we recognized a need for better and personalized predictive patient care and an opportunity to leverage the microbiome to enable safer and more efficacious drug therapies. We started AlphaBiomics with the mission to develop microbiome-based precision medicine solutions that will predict drug response and improve drug therapy.